非甾体抗炎药在EORTC 1325/KEYNOTE-054 III期试验中帕博利珠单抗对比安慰剂治疗已切除高危III期黑色素瘤的预后与预测价值
本研究基于EORTC 1325/KEYNOTE-054 III期试验,评估非甾体抗炎药(NSAIDs)与已切除高危III期黑色素瘤患者无复发生存(RFS)、无远处转移生存(DMFS)及免疫相关不良事件(irAEs)的关联。结果显示,在帕博利珠单抗辅助治疗患者中,NSAIDs与疗效结局及irAEs风险均无显著关联。
要点
- 在帕博利珠单抗组,NSAIDs与RFS(HR 0.91,95% CI 0.58-1.43)和DMFS(HR 1.03,95% CI 0.65-1.66)无显著关联。
- 在安慰剂组,NSAIDs与RFS(HR 0.76,95% CI 0.48-1.20)和DMFS(HR 0.80,95% CI 0.49-1.31)无显著关联。
- 在安慰剂组,NSAIDs与irAEs发生率相关(HR 3.06,95% CI 1.45-6.45),但在帕博利珠单抗组无此关联(HR 0.94,95% CI 0.58-1.53)。
核心结论
- 在已切除高危III期黑色素瘤接受帕博利珠单抗辅助治疗的患者中,NSAIDs与疗效结局及irAEs风险均无显著关联。
研究设计与样本
- EORTC 1325/KEYNOTE-054 III期临床试验,纳入AJCC7 IIIA、IIIB或IIIC期已切除黑色素瘤患者,随机接受200 mg帕博利珠单抗(N=514)或安慰剂(N=505)每3周一次治疗一年或直至复发。
- NSAIDs使用定义为随机化前7天至开始治疗期间给药。
- 采用多变量Cox和Fine and Gray模型估计NSAIDs与RFS、DMFS及irAEs关联的风险比(HR)。
主要发现
- 1019例随机患者中,帕博利珠单抗组59例和安慰剂组44例使用NSAIDs。
- 帕博利珠单抗组:NSAIDs与RFS无显著关联(HR 0.91,95% CI 0.58-1.43),与DMFS无显著关联(HR 1.03,95% CI 0.65-1.66)。
- 安慰剂组:NSAIDs与RFS无显著关联(HR 0.76,95% CI 0.48-1.20),与DMFS无显著关联(HR 0.80,95% CI 0.49-1.31)。
- 安慰剂组:NSAIDs与irAEs发生率相关(HR 3.06,95% CI 1.45-6.45);帕博利珠单抗组:NSAIDs与irAEs无显著关联(HR 0.94,95% CI 0.58-1.53)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain is common in patients with cancer. The World Health Organisation recommends paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for mild pain and combined with other agents for moderate/severe pain. This study estimated associations of NSAIDs with recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and the incidence of immune-related adverse events (irAEs) in high-risk patients with resected melanoma in the EORTC 1325/KEYNOTE-054 phase III clinical trial. PATIENTS AND METHODS: Patients with AJCC7 stage IIIA, IIIB or IIIC resected melanoma were randomized to receive 200 mg of adjuvant pembrolizumab (N = 514) or placebo (N = 505) 3-weekly for one year or until recurrence. As previously reported, pembrolizumab prolonged RFS and DMFS. NSAID use was defined as administration between 7 days pre-randomization and starting treatment. Multivariable Cox and Fine and Gray models were used to estimate hazard ratios (HRs) for associations of NSAIDs with RFS, DMFS and irAEs. RESULTS: Of 1019 patients randomized, 59 and 44 patients in the pembrolizumab and placebo arms, respectively, used NSAIDs. NSAIDs were not associated with RFS (HR 0.91, 95% CI 0.58-1.43) or DMFS in the pembrolizumab (HR 1.03, 95% CI 0.65-1.66) or placebo arms (for RFS, HR 0.76, 95% CI 0.48-1.20; for DMFS, HR 0.80, 95% CI 0.49-1.31). NSAIDs were associated with the incidence of irAEs in the placebo arm (HR 3.06, 95% CI 1.45-6.45) but not in the pembrolizumab arm (HR 0.94, 95% CI 0.58-1.53). CONCLUSION: NSAIDs were not associated with efficacy outcomes nor the risk of irAEs in patients with resected high-risk stage III melanoma receiving adjuvant pembrolizumab.
引用
- Kennedy OJ, Glassee N, Kicinski M, et al. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2024. PMID: 38402687. doi:10.1016/j.ejca.2024.113585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。